ATTR cardiomyopathy — treatment timing, adoption and durable growthNovember 11, 2026

Alnylam’s Five-Year HELIOS-B Data: Can Earlier Treatment Drive Durable Growth?

ALNY

Executive Summary

Alnylam’s five-year HELIOS-B update strengthens the case for earlier vutrisiran treatment in ATTR cardiomyopathy. For ALNY investors, the next test is whether better diagnosis and earlier prescribing translate into patient starts, durable access and sustained revenue. Clinical benefit, combination use and commercial growth require separate assumptions. BioScore unverified; no editorial investment rating assigned.

BioStockEdge | Editor’s Note | ALNY

Evidence cutoff: November 11, 2026

Alnylam’s five-year HELIOS-B update strengthens the clinical argument for starting vutrisiran earlier in ATTR cardiomyopathy. For investors, the relevant question is whether that evidence changes treatment decisions soon enough to generate additional patient starts, sustained access and durable revenue.

That is a commercial hypothesis. The trial does not establish how much revenue the new evidence will produce, or whether the equity market has already priced it in.

What the comparison actually measures

On November 9, Alnylam (Nasdaq: ALNY) reported a hazard ratio of 0.589 for all-cause mortality and recurrent cardiovascular events in the overall HELIOS-B population, comparing patients originally assigned vutrisiran with those originally assigned placebo and eligible to start vutrisiran in the extension. The nominal P values were not adjusted for multiplicity.[1]

The approximately 41% relative reduction applies to that composite. It is not a 41% reduction in mortality alone. Nor is this five years of uninterrupted placebo control.

The extension presentation supplies useful absolute context: 156 of 326 patients in the earlier-treatment group and 211 of 328 in the delayed-treatment group had at least one composite event. These are crude observed proportions, not adjusted five-year cumulative risks. Only 466 patients entered the open-label extension.[2]

The distinction matters. Original randomization supports interpretation of the treatment pathways, while subsequent survival, participation, missing data and treatment changes complicate the extension. A persistent cumulative gap also cannot isolate the benefit obtained after crossover. Earlier events remain in the record even if later treatment reduces subsequent risk.

The commercial proposition: change when physicians start therapy

Our interpretation is that the update strengthens an argument against routinely postponing vutrisiran until further clinical deterioration. If physicians and payers act on that argument, treatment could begin earlier in an eligible patient’s disease course.

But earlier initiation does not automatically mean a larger market share or a longer realized treatment duration. Diagnosis, competing therapies, reimbursement rules, tolerability and persistence still determine which patients actually start and remain on treatment. The update provides clinical support for a commercial strategy; prescribing and access data must establish whether it works.

For investors, diagnosis belongs in that commercial model. The relevant funnel runs from recognition of ATTR-CM to confirmed diagnosis, treatment eligibility, reimbursement, initiation and persistence. A larger estimate of the disease population does not by itself establish how many patients can enter that funnel or how quickly they will do so.

Alnylam’s recent disclosures make that distinction tangible. Its second-quarter announcement lowered full-year TTR sales guidance, citing normalization of second-line volume after pent-up demand was addressed.[3] In the third quarter, AMVUTTRA global net product revenue was $1.130 billion. U.S. TTR revenue growth included demand, inventory and favorable gross-to-net effects.[4]

Those reported revenues cover more than the incremental ATTR-CM opportunity addressed by this update. They cannot be treated as sales attributable to the five-year evidence or as an ATTR-CM-only run rate. The evidence was announced after the third quarter ended.

Combination therapy remains a separate underwriting question

In the baseline-tafamidis subgroup, the composite HR was 0.744, with a 95% confidence interval of 0.516–1.073. Recurrent cardiovascular events favored continuous earlier addition of vutrisiran, with a relative rate ratio of 0.766.[1,2]

These findings should not be collapsed into a claim that combination therapy has conclusively improved every important outcome. They compare earlier versus delayed addition within the trial’s treatment pathways, not a newly randomized five-year combination-versus-monotherapy strategy.

A commercial model should therefore distinguish use of vutrisiran without a stabilizer, switching from a stabilizer, and adding it to an existing stabilizer. These paths carry different evidence, access and economic assumptions. The trial does not establish the best sequence for every patient.

The competitive context has changed

Tafamidis and acoramidis are approved oral TTR stabilizers; vutrisiran is an approved TTR silencer given quarterly.[5–7] HELIOS-B does not provide a head-to-head ranking among them.

Another important 2026 development was CARDIO-TTRansform: AstraZeneca reported that eplontersen failed its primary composite endpoint in ATTR-CM. Most participants received background stabilizer therapy.[8] Eplontersen uses an antisense approach rather than vutrisiran’s siRNA approach. Different trial populations, background treatment and endpoints prevent a simple cross-trial efficacy verdict.

The lesson for underwriting is product-specific: reducing TTR production does not eliminate the need to demonstrate clinical benefit in the intended treatment setting. Eplontersen’s result neither invalidates HELIOS-B nor proves that vutrisiran must prevail commercially.

What would change the investment assessment next?

We would look for evidence that earlier use is occurring: new patient starts, first-line treatment patterns where disclosed, payer access and persistence. We would separate demand from inventory and net-price effects, and avoid inferring patient counts directly from revenue.

Longer term, Alnylam’s next-generation RNAi program nucresiran must earn its own clinical evidence. The company expanded TRITON-CM target enrollment to approximately 2,250 patients in October; its launch expectations remain conditional on positive data and regulatory approval.[4]

The five-year HELIOS-B update adds weight to vutrisiran’s clinical positioning. A higher revenue forecast or valuation requires additional assumptions about adoption, access, price, duration and competition. Those assumptions should be visible, tested against subsequent disclosures and kept separate from the trial result itself.

Further reading

For the disease mechanism, diagnostic pathway and patient-facing interpretation, read our Chinese-language companion article at 结论之外.

Original sources

[1] Alnylam, five-year HELIOS-B update, November 9, 2026.

[2] Cuddy et al., AHA 2026 presentation, PDF pp. 4–8.

[3] Alnylam Q2 2026 results, July 30, 2026.

[4] Alnylam Q3 2026 results, October 29, 2026, SEC exhibit.

[5] FDA, tafamidis label.

[6] FDA, acoramidis approval.

[7] FDA, vutrisiran approval record.

[8] AstraZeneca, CARDIO-TTRansform update, July 9, 2026.

This note distinguishes company disclosures from our interpretation. It assigns no price target or investment recommendation and does not validate an automatically generated platform rating.

BioScore

8/10
Strong Buy